Koenig F - Search Results

1

Analytical aspects regarding the measurement of metalloproteinases and their inhibitors in blood.

Lein M, Nowak L, Jung K, Koenig F, Lichtinghagen R, Schnorr D, Loening SA. Lein M, et al. Among authors: koenig f. Clin Biochem. 1997 Aug;30(6):491-6. doi: 10.1016/s0009-9120(97)00097-0. Clin Biochem. 1997. PMID: 9316744 Clinical Trial.

2

[Metalloproteinases (MMP-1, MMP-3) and their inhibitors (TIMP) in blood plasma of patients with prostate carcinoma].

Lein M, Nowak L, Jung K, Koenig F, Schnorr D, Loening SA. Lein M, et al. Among authors: koenig f. Urologe A. 1998 Jul;37(4):377-81. doi: 10.1007/s001200050194. Urologe A. 1998. PMID: 9738289 German.

3

The percentage of free prostate specific antigen is an age-independent tumour marker for prostate cancer: establishment of reference ranges in a large population of healthy men.

Lein M, Koenig F, Jung K, McGovern FJ, Skates SJ, Schnorr D, Loening SA. Lein M, et al. Among authors: koenig f. Br J Urol. 1998 Aug;82(2):231-6. doi: 10.1046/j.1464-410x.1998.00723.x. Br J Urol. 1998. PMID: 9722758

4

Urinary markers of malignancy.

Koenig F, Jung K, Schnorr D, Loening SA. Koenig F, et al. Clin Chim Acta. 2000 Jul;297(1-2):191-205. doi: 10.1016/s0009-8981(00)00246-1. Clin Chim Acta. 2000. PMID: 10841921 Review.

5

Excretion of matrix metalloproteinases 2 and 9 in urine is associated with a high stage and grade of bladder carcinoma.

Gerhards S, Jung K, Koenig F, Daniltchenko D, Hauptmann S, Schnorr D, Loening SA. Gerhards S, et al. Among authors: koenig f. Urology. 2001 Apr;57(4):675-9. doi: 10.1016/s0090-4295(00)01087-6. Urology. 2001. PMID: 11306379 Clinical Trial.

6

Elimination of serum free and total prostate-specific antigen after radical retropubic prostatectomy.

Lein M, Brux B, Jung K, Henke W, Koenig F, Stephan C, Schnorr D, Loening SA. Lein M, et al. Among authors: koenig f. Eur J Clin Chem Clin Biochem. 1997 Aug;35(8):591-5. doi: 10.1515/cclm.1997.35.8.591. Eur J Clin Chem Clin Biochem. 1997. PMID: 9298348

7

Cathepsins B, H, and L activities in urine of patients with transitional cell carcinoma of the bladder.

Staack A, Koenig F, Daniltchenko D, Hauptmann S, Loening SA, Schnorr D, Jung K. Staack A, et al. Among authors: koenig f. Urology. 2002 Feb;59(2):308-12. doi: 10.1016/s0090-4295(01)01517-5. Urology. 2002. PMID: 11834417

8

Correspondence re: C. F. M. Sier et al., Enhanced urinary gelatinase activities (matrix metalloproteinases 2 and 9) are associated with early-stage bladder carcinoma: a comparison with clinically used tumor markers. Clin. Cancer Res., 6: 2333-2340, 2000.

Gerhards S, Jung K, Koenig F, Daniltchenko D, Hauptmann S, Schnorr D, Loening SA. Gerhards S, et al. Among authors: koenig f. Clin Cancer Res. 2001 Feb;7(2):445-7. Clin Cancer Res. 2001. PMID: 11234903 No abstract available.

9

Confocal laser scanning microscopy of urinary bladder after intravesical instillation of a fluorescent dye.

Koenig F, Knittel J, Schnieder L, George M, Lein M, Schnorr D. Koenig F, et al. Urology. 2003 Jul;62(1):158-61. doi: 10.1016/s0090-4295(03)00121-3. Urology. 2003. PMID: 12837458

10

Long-term benefit of 5-aminolevulinic acid fluorescence assisted transurethral resection of superficial bladder cancer: 5-year results of a prospective randomized study.

Daniltchenko DI, Riedl CR, Sachs MD, Koenig F, Daha KL, Pflueger H, Loening SA, Schnorr D. Daniltchenko DI, et al. Among authors: koenig f. J Urol. 2005 Dec;174(6):2129-33, discussion 2133. doi: 10.1097/01.ju.0000181814.73466.14. J Urol. 2005. PMID: 16280742 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

188 results

Search Page

Filters